← Leaderboards
Philippe Andre Gallay
Scripps Research Institute
$24,442,648
Attributed
$24,442,648
Total exposure
18
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,442,648 · 18
By mechanism
R01$16,033,398 · 9
R33$4,774,946 · 3
R21$3,634,304 · 6
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- Juan C. De La Torre$34,810,527
- Michael B Oldstone$35,619,947
- Erica Ollmann Saphire$52,684,297
- Michael Buchmeier$13,319,318
- Jason W. Botten$9,089,641
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusIn VitroPreventIn VivoMediatingViralCellsAntiviral AgentsResistanceInfectionHepatitis C VirusInhibitor/AntagonistMembranePlayPropertyBinding (Molecular Function)MicrobicideDoseHiv InfectionsGenital SystemMacacaVaginaDendritic CellsPharmaceutical Preparations
Grant awards (56)
A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19$749,787
R01 · FY2025 · AI · contact PI
A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19$775,538
R01 · FY2024 · AI · contact PI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development$452,500
R01 · FY2024 · AI · contact PI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development$443,750
R01 · FY2023 · AI · contact PI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development$443,750
R01 · FY2022 · AI · contact PI
Analyses of the Antiviral and Antifibrotic Mechanisms of Action of NS5A and Cyclophilin Inhibitors$481,250
R01 · FY2021 · AI · contact PI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development$443,750
R01 · FY2021 · AI · contact PI
Analyses of the Antiviral and Antifibrotic Mechanisms of Action of NS5A and Cyclophilin Inhibitors$481,250
R01 · FY2020 · AI · contact PI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development$443,750
R01 · FY2020 · AI · contact PI
Analyses of the Antiviral and Antifibrotic Mechanisms of Action of NS5A and Cyclophilin Inhibitors$481,250
R01 · FY2019 · AI · contact PI
Analyses of the Antiviral and Antifibrotic Mechanisms of Action of NS5A and Cyclophilin Inhibitors$481,250
R01 · FY2018 · AI · contact PI
Analyses of the Antiviral and Antifibrotic Mechanisms of Action of NS5A and Cyclophilin Inhibitors$481,250
R01 · FY2017 · AI · contact PI
Cyclophilins and the IFN Response$401,255
R01 · FY2017 · AI · contact PI
Cyclophilins and the IFN Response$401,255
R01 · FY2016 · AI · contact PI
Cyclophilins and the IFN Response$395,001
R01 · FY2015 · AI · contact PI
Cyclophilins, Cyclophilin Inhibitors and Hepatitis C$470,003
R01 · FY2014 · AI · contact PI
C5a as an Anti-HIV Microbicidal Candidate$470,003
R01 · FY2014 · AI · contact PI
Cyclophilins and the IFN Response$395,001
R01 · FY2014 · AI · contact PI
Anti-HIV Microbicidal Peptides$485,860
R33 · FY2013 · AI · contact PI
C5a as an Anti-HIV Microbicidal Candidate$448,543
R01 · FY2013 · AI · contact PI
Cyclophilins, Cyclophilin Inhibitors and Hepatitis C$441,802
R01 · FY2013 · AI · contact PI
Anti-HIV Microbicidal Peptides$519,045
R33 · FY2012 · AI · contact PI
C5a as an Anti-HIV Microbicidal Candidate$470,003
R01 · FY2012 · AI · contact PI
Cyclophilins, Cyclophilin Inhibitors and Hepatitis C$470,003
R01 · FY2012 · AI · contact PI
Anti-HIV Microbicidal Peptides$554,125
R33 · FY2011 · AI · contact PI
Inhibitors of HIV-Dendritic Cell Interactions as Microbicides$521,756
R33 · FY2011 · AI · contact PI
Cyclophilins, Cyclophilin Inhibitors and Hepatitis C$470,003
R01 · FY2011 · AI · contact PI
C5a as an Anti-HIV Microbicidal Candidate$470,003
R01 · FY2011 · AI · contact PI
Anti-HIV Microbicidal Peptides$618,237
R21 · FY2010 · AI · contact PI
Inhibitors of HIV-Dendritic Cell Interactions as Microbicides$527,027
R33 · FY2010 · AI · contact PI
Syndecan Agonists and Antagonists as Microbicides$526,433
R33 · FY2010 · AI · contact PI
C5a as an Anti-HIV Microbicidal Candidate$474,750
R01 · FY2010 · AI · contact PI
Cyclophilins, Cyclophilin Inhibitors and Hepatitis C$474,750
R01 · FY2010 · AI · contact PI
Inhibitors of HIV-Dendritic Cell Interactions as Microbicides$554,825
R33 · FY2009 · AI · contact PI
Syndecan Agonists and Antagonists as Microbicides$531,750
R33 · FY2009 · AI · contact PI
Virocide as an Anti-HIV Microbicide Candidate$451,431
R21 · FY2009 · AI · contact PI
Anti-HIV Microbicidal Peptides$284,850
R21 · FY2009 · AI · contact PI
Virocide as an Anti-HIV Microbicide Candidate$284,250
R21 · FY2009 · AI · contact PI
Syndecan Agonists and Antagonists as Microbicides$554,125
R33 · FY2008 · AI · contact PI
Virocide as an Anti-HIV Microbicide Candidate$236,875
R21 · FY2008 · AI · contact PI
Inhibitors of HIV-Dendritic Cell Interactions as Microbicides$224,063
R21 · FY2008 · AI · contact PI
Microenvironment Modulates HIV Replication in Macrophage$440,667
R01 · FY2007 · AI · contact PI
Inhibitors of HIV-Dendritic Cell Interactions as Microbicides$279,600
R21 · FY2007 · AI · contact PI
Syndecan Agonists and Antagonists as Microbicides$258,579
R21 · FY2007 · AI · contact PI
Microenvironment Modulates HIV Replication in Macrophage$453,828
R01 · FY2006 · AI · contact PI
Heparan Sulfate Proteoglycans and HIV Pathogenesis$366,578
R01 · FY2006 · AI · contact PI
Syndecan Agonists and Antagonists as Microbicides$221,918
R21 · FY2006 · AI · contact PI
Microenvironment Modulates HIV Replication in Macrophage$464,750
R01 · FY2005 · AI
Heparan Sulfate Proteoglycans and HIV Pathogenesis$375,400
R01 · FY2005 · AI
Microenvironment Modulates HIV Replication in Macrophage$469,250
R21 · FY2004 · AI
Heparan Sulfate Proteoglycans and HIV Pathogenesis$375,400
R01 · FY2004 · AI
Heparan Sulfate Proteoglycans and HIV Pathogenesis$375,400
R01 · FY2003 · AI
ROLE OF CYCLOPHILIN A IN THE HIV-1 LIFE CYCLE$310,275
R01 · FY2003 · AI
ROLE OF CYCLOPHILIN A IN THE HIV-1 LIFE CYCLE$310,275
R01 · FY2002 · AI
ROLE OF CYCLOPHILIN A IN THE HIV-1 LIFE CYCLE$149,375
R01 · FY2001 · AI
ROLE OF CYCLOPHILIN A IN THE HIV-1 LIFE CYCLE$305,251
R21 · FY2000 · AI